n.c.a. Lutetium-177 (Lu-177)

n.c.a. Lutetium-1772022-10-27T13:42:32-05:00


SHINE Technologies’ isotope production process is enabling treatment options that have the potential to improve outcomes for patients being treated for a range of cancers, such as prostate cancer. SHINE’s current focus includes production of non-carrier-added lutetium-177. The unique advantages of our n.c.a. Lu-177 production process include an exclusive processing technology, flexibility for irradiation, stable isotope enrichment capability, fewer logistical challenges in transport, and a cleaner and safer production method.

SHINE Lu-177 Product Box 3
Download our brochure to learn more about Lu-177

Therapeutics in the news

Go to Top